ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 675,62
-0,26%
Dow Jones
39 375,87
0,17%
DAX
18 475,45
0,12%
Brent Oil
86,775
0,00%
Bitcoin
56 555,80
-0,16%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vicuron Pharmaceuticals (MM) (MICU)

  7. Vicuron Pharmaceuticals (MM) (MICU) Actualités

MICU

Vicuron (MICU)

Vicuron Pharmaceuticals (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MICU
DateHeureSourceTitreSymboleSociété
14/09/200510h00PR Newswire (US)Pfizer Completes Acquisition of Vicuron PharmaceuticalsNASDAQ:MICU
11/09/200519h00PR Newswire (US)Vicuron Pharmaceuticals - Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Expected Closing Date for AcquisitionNASDAQ:MICU
18/08/200523h30PR Newswire (US)Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/CandidemiaNASDAQ:MICU
15/08/200523h30PR Newswire (US)Vicuron Pharmaceuticals Stockholders Approve Merger With PfizerNASDAQ:MICU
04/08/200523h30PR Newswire (US)Vicuron Pharmaceuticals Announces Second Quarter 2005 Financial ResultsNASDAQ:MICUVicuron Pharmaceuticals (MM)
16/06/200508h00PR Newswire (US)Pfizer to Acquire Vicuron Pharmaceuticals to Extend its Research Commitment in Anti-InfectivesNASDAQ:MICUVicuron Pharmaceuticals (MM)
02/06/200509h00PR Newswire (US)Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark OfficeNASDAQ:MICU
31/05/200509h00PR Newswire (US)Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal CandidiasisNASDAQ:MICU
26/05/200523h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference and the Pacific GrowthNASDAQ:MICU
17/05/200523h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 2005 Needham Biotech ConferenceNASDAQ:MICU
11/05/200509h00PR Newswire (US)Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug ApplicationNASDAQ:MICU
09/05/200523h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Bear Stearns 2005 Healthcare Conference and the Banc of America Securities HealthcareNASDAQ:MICU
05/05/200523h30PR Newswire (US)Vicuron Pharmaceuticals Announces First Quarter 2005 Financial ResultsNASDAQ:MICU
28/04/200514h30PR Newswire (US)Vicuron Pharmaceuticals to Present at Morgan Stanley Healthcare Unplugged ConferenceNASDAQ:MICU
31/03/200500h30PR Newswire (US)Vicuron Pharmaceuticals Extends Pfizer Deal to Develop Oral Antibiotics for Community MarketNASDAQ:MICU
10/03/200522h30PR Newswire (US)Vicuron Pharmaceuticals Announces Fourth Quarter 2004 Financial ResultsNASDAQ:MICU
10/03/200513h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the SG Cowen & Co. 25th Annual Health Care ConferenceNASDAQ:MICU
04/03/200508h00PR Newswire (US)Vicuron Pharmaceuticals Provides Update on Novartis Peptide Deformylase Inhibitor ProgramNASDAQ:MICU
25/02/200513h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Wells Fargo Securities Healthcare ConferenceNASDAQ:MICU
24/02/200508h00PR Newswire (US)Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue InfectionsNASDAQ:MICU
17/02/200513h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the BIO CEO & Investor Conference 2005NASDAQ:MICU
07/02/200508h00PR Newswire (US)Vicuron Pharmaceuticals Announces Phase 3 Trial Results Demonstrate Superiority of Anidulafungin Versus Fluconazole in InvasiveNASDAQ:MICU
24/01/200508h00PR Newswire (US)Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to Executive Vice President and Chief Medical OfficerNASDAQ:MICU
05/01/200513h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 23rd Annual JP Morgan Healthcare ConferenceNASDAQ:MICU
21/12/200422h30PR Newswire (US)Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug AdministrationNASDAQ:MICU
29/11/200413h30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Lazard Freres & Co. Healthcare ConferenceNASDAQ:MICU
04/11/200422h30PR Newswire (US)Vicuron Pharmaceuticals Announces Third Quarter 2004 Financial ResultsNASDAQ:MICU
01/11/200408h00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Supporting Next-Generation Lincosamide ProgramNASDAQ:MICU
01/11/200408h00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Demonstrating Potency of Anidulafungin and DalbavancinNASDAQ:MICU
25/10/200414h30PR Newswire (US)Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC Highlighting Pipeline and Late-Stage ProductsNASDAQ:MICU
 Showing the most relevant articles for your search:NASDAQ:MICU

Dernières Valeurs Consultées

BIT
UC045V
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés